glp-1 cardiovascular outcomes 2025 news ISPOR 2025: Exploring reasons for discontinuation An Observational Study of Cardiovascular

10.1016/j.atherosclerosis.2023.03.016 26

GLP-1 therapy has milder, reversible side effects

The pharmacological goal in every case is to reduce blood glucose toward the normal range without swinging too far in the other direction into hypoglycemia

At day 6 after the first infusion, the semaglutide-treated and GLP-1MK-801-treated mice were crossed-over in terms of treatment and administered with another single infusion of either GLP-1MK-801 (0.22 nmol, 2 l) and semaglutide (0.22 nmol, 2 l), respectively, while vehicle-treated mice received vehicle treatment once again

[DOI] [PMC free article] [PubMed] [Google Scholar] 148.Di Francesco V., Barazzoni R., Bissoli L., Fantin F., Rizzotti P., Residori L., Antonioli A., Graziani M.S., Zanetti M., Bosello O., et al

Contamination by microorganisms can lead to the production of proteases that rapidly digest Retatrutide